TLR7 ligand augments GM-CSF-initiated antitumor immunity through activation of plasmacytoid dendritic cells

Cancer Immunology Research

Volumn 2, Issue 6, 2014, Pages 568-580

  Narusawa, Megumi ^a   Inoue, Hiroyuki ^a,b   Sakamoto, Chika ^a   Matsumura, Yumiko ^a   Takahashi, Atsushi ^a   Inoue, Tomoko ^a   Watanabe, Ayumi ^a   Miyamoto, Shohei ^a   Miura, Yoshie ^a   Hijikata, Yasuki ^b   Tanaka, Yoshihiro ^b   Inoue, Makoto ^c   Takayama, Koichi ^a   Okazaki, Toshihiko ^b   Hasegawa, Mamoru ^c   Nakanishi, Yoichi ^a   Tani, Kenzaburo ^a,b  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY HOSPITAL   (Japan)

^c DNAVEC Corporation   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; AMINOQUINOLINE DERIVATIVE; CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIQUIMOD; INTERFERON; INTERFERON INDUCING AGENT; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; TLR7 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 7;

ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; CANCER TRANSPLANTATION; CARCINOMA, LEWIS LUNG; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DEFICIENCY; DENDRITIC CELL; DNA MICROARRAY; FEMALE; GENE VECTOR; GENETIC TRANSFECTION; IMMUNOLOGY; IMMUNOTHERAPY; KNOCKOUT MOUSE; METABOLISM; PROCEDURES; SENDAI VIRUS; TUMOR CELL LINE; UPREGULATION;

AMINOQUINOLINES; ANIMALS; ANTIGENS, CD; CANCER VACCINES; CARCINOMA, LEWIS LUNG; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DENDRITIC CELLS; FEMALE; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOTHERAPY; INTERFERON INDUCERS; INTERFERON TYPE I; MEMBRANE GLYCOPROTEINS; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR, INTERFERON ALPHA-BETA; SENDAI VIRUS; TOLL-LIKE RECEPTOR 7; TRANSFECTION; UP-REGULATION;

EID: 84990009567     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-13-0143     Document Type: Article

References (42)

1. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993; 90:3539-43.
2. Tani K, Azuma M, Nakazaki Y, Oyaizu N, Hase H, Ohata J, et al. Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings. Mol Ther 2004; 10:799-816.
3. Longo DL New therapies for castration-resistant prostate cancer. N Engl J Med 2010; 363:479-81.
4. Li HO, Zhu YF, Asakawa M, Kuma H, Hirata T, Ueda Y, et al. A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. J Virol 2000; 74: 6564-9.
5. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005; 434:772-7.
6. Inoue H, Iga M, Nabeta H, Yokoo T, Suehiro Y, Okano S, et al. Nontransmissible Sendai virus encoding granulocyte macrophage colony-stimulating factor is a novel and potent vector system for producing autologous tumor vaccines. Cancer Sci 2008; 99: 2315-26.
7. Yoneyama H, Matsuno K, Toda E, Nishiwaki T, Matsuo N, Nakano A, et al. Plasmacytoid DCs help lymph node DCs to induce anti-HSV CTLs. J Exp Med 2005; 202:425-35.
8. Yokota Y, Inoue H, Matsumura Y, Nabeta H, Narusawa M, Watanabe A, et al. Absence of LTB4/BLT1 axis facilitates generation of mouse GMCSF-induced long-lastingantitumorimmunologic memory byenhancing innate and adaptive immune systems. Blood 2012; 120:3444-54.
9. Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol 2008; 8:559-68.
10. Gilliet M, Cao W, Liu YJ. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 2008; 8:594-606.
11. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol 2004; 5:1219-26.
12. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003; 85:85-95.
13. Takagi H, Fukaya T, Eizumi K, Sato Y, Sato K, Shibazaki A, et al. Plasmacytoid dendritic cells are crucial for the initiation of inflammation and T cell immunity in vivo. Immunity 2011; 35:958-71.
14. Bjorck P, Leong HX, Engleman EG. Plasmacytoid dendritic cell dichotomy: identification of IFN-alpha producing cells as a phenotypically and functionally distinct subset. J Immunol 2011; 186:1477-85.
15. Shi L, Chen J, Zhong Q, Li M, Geng P, He J, et al. Inactivated Sendai virus strain Tianjin, a novel genotype of Sendai virus, inhibits growth of murine colon carcinoma through inducing immune responses and apoptosis. J Transl Med 2013; 11:205.
16. Sumimoto H, Tani K, Nakazaki Y, Tanabe T, Hibino H, Hamada H, et al. GM-CSF and B7-1 (CD80) co-stimulatory signals co-operate in the induction of effective anti-tumor immunity in syngeneic mice. Int J Cancer 1997; 73:556-61.
17. Wada H, Noguchi Y, Marino MW, Dunn AR, Old LJ. T cell functions in granulocyte/macrophage colony-stimulating factor deficient mice. Proc Natl Acad Sci U S A 1997; 94:12557-61.
18. Yang H, Wei J, Zhang H, Lin L, Zhang W, He S. Upregulation of Toll-like receptor (TLR) expression and release of cytokines from P815 mast cells by GM-CSF. BMC Cell Biol 2009; 10:37.
19. Barreda DR, Hanington PC, Belosevic M. Regulation of myeloid development and function by colony stimulating factors. Dev Comp Immunol 2004; 28:509-54.
20. Kingston D, Schmid MA, Onai N, Obata-Onai A, Baumjohann D, Manz MG. The concerted action of GM-CSF and Flt3-ligand on in vivo dendritic cell homeostasis. Blood 2009; 114:835-43.
21. Mausberg AK, Jander S, Reichmann G. Intracerebral granulocytemacrophage colony-stimulating factor induces functionally competent dendritic cells in the mouse brain. Glia 2009; 57:1341-50.
22. Daro E, Pulendran B, Brasel K, Teepe M, Pettit D, Lynch DH, et al. Polyethylene glycol-modified GM-CSF expands CD11b(high)CD11c (high) but notCD11b(low)CD11c(high) murine dendritic cells in vivo: a comparative analysis with Flt3 ligand. J Immunol 2000; 165:49-58.
23. Esashi E, Wang YH, Perng O, Qin XF, Liu YJ, Watowich SS. The signal transducer STAT5 inhibits plasmacytoid dendritic cell development by suppressing transcription factor IRF8. Immunity 2008; 28:509-20.
24. - murine plasmacytoid DC precursors with plasticity to differentiate into conventional DCs. Blood 2011; 117: 6562-70.
25. Ghirelli C, Zollinger R, Soumelis V. Systematic cytokine receptor profiling reveals GM-CSF as a novel TLR-independent activator of human plasmacytoid predendritic cells. Blood 2010; 115:5037-40.
26. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005; 5:296-306.
27. Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004; 114:280-90.
28. Labidi-Galy S I, Sisirak V, Meeus P, Gobert M, Treilleux I, Bajard A, et al. Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res 2011; 71:5423-34.
29. Zou W, Machelon V, Coulomb-L'Hermin A, Borvak J, Nome F, Isaeva T, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001; 7: 1339-46.
30. Kim R, Emi M, Tanabe K, Arihiro K. Potential functional role of plasmacytoid dendritic cells in cancer immunity. Immunology 2007; 121: 149-57.
31. Villadangos JA, Young L. Antigen-presentation properties of plasmacytoid dendritic cells. Immunity 2008; 29:352-61.
32. +, T cells by plasmacytoid dendritic cells. J Exp Med 2007; 204:1923-33.
33. Di Pucchio T, Chatterjee B, Smed-Sorensen A, Clayton S, Palazzo A, Montes M, et al. Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I. Nat Immunol 2008; 9:551-7.
34. Palamara F, Meindl S, Holcmann M, Luhrs P, Stingl G, Sibilia M. Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J Immunol 2004; 173: 3051-61.
35. + T-cell reactivity in melanoma patients. Clin Cancer Res 2008; 14:4532-42.
36. +0201 matched allogeneic plasmacytoid dendritic cells. PLoS ONE 2010; 5:e10458.
37. Drobits B, Holcmann M, Amberg N, Swiecki M, Grundtner R, Hammer M, et al. Imiquimod clears tumors in mice independent of adaptive mmunity by converting pDCs into tumor-killing effector cells. J Clin Invest 2012; 122:575-85.
38. + T cells: a new role for plasmacytoid dendritic cells in adaptive immunity. Blood 2003; 101:3520-6.
39. + T cells stimulated by virus-induced type I nterferon. Nat Immunol 2003; 4:1009-15.
40. Honda K, Sakaguchi S, Nakajima C, Watanabe A, Yanai H, Matsumoto M, et al. Selective contribution of IFN-alpha/beta signaling to the maturation of dendritic cells induced by double-stranded RNA or viral nfection. Proc Natl Acad Sci U S A 2003; 100:10872-7.
41. Blasius AL, Cella M, Maldonado J, Takai T, Colonna M. Siglec-H is an IPC-specific receptor that modulates type I IFN secretion through DAP12. Blood 2006; 107:2474-6.
42. Dang Y, Wagner WM, Gad E, Rastetter L, Berger CM, Holt GE, et al. Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells. Clin Cancer Res 2012; 18:3122-31.